Physician profile
Deena Graham
NPI 1790716926
$8,094.46
in general payments reported to CMS, 2019-2025
33 companies · $666 in 2025
The $666 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,242 · 2020: $66.76 · 2021: $2,259 · 2022: $1,118 · 2023: $1,055 · 2024: $688 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $4,076.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $978.82 | 2019-2023 | |
| Daiichi Sankyo INC. | $799.26 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Gilead Sciences, INC. | $370.47 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $318.44 | 2021-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $291.00 | 2020-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $186.99 | 2019-2024 | Keytruda, Lynparza |
| Seagen INC. | $176.42 | 2021-2023 | Tukysa |
| Pfizer INC. | $148.39 | 2024-2025 | |
| Astrazeneca Uk Limited | $135.00 | 2022 | |
| Abbvie INC. | $103.14 | 2024-2025 | |
| Mirati Therapeutics, INC. | $95.21 | 2023-2024 | Krazati |
| Fennec Pharmaceuticals, INC. | $52.67 | 2025 | Fyarro |
| Genentech USA, INC. | $44.34 | 2019 | |
| Foundation Medicine, INC. | $43.79 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $34.82 | 2023 | Empaveli |
| Janssen Biotech, INC. | $29.49 | 2019-2022 | |
| Amgen INC. | $29.19 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Novo Nordisk INC | $24.90 | 2022 | |
| Stemline Therapeutics INC. | $24.38 | 2024 | Orserdu |
| Rigel Pharmaceuticals, INC. | $22.38 | 2024 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $18.79 | 2023 | Jaypirca, Verzenio |
| Taiho Oncology, INC. | $18.64 | 2024 | |
| Macrogenics, INC. | $17.64 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.25 | 2025 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $13.80 | 2022 | |
| Heron Therapeutics, INC. | $13.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.05 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deena Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.